Drugs / TAK-103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05164666 | Jan 2022 → Feb 2025 | cancer | Takeda | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05164666 ↗ |
| Modality | Cell therapy | “TAK-103, Chimeric antigen receptor (CAR) (+) cells” NCT05164666 ↗ |
| Route | Intravenous | “TAK-103 intravenous infusion” NCT05164666 ↗ |